A5003241020- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral Infections and Vectors
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Viral Infections and Outbreaks Research
- Mosquito-borne diseases and control
- COVID-19 epidemiological studies
- Infection Control and Ventilation
- Vector-Borne Animal Diseases
- Virology and Viral Diseases
- Fire effects on ecosystems
- Neonatal Respiratory Health Research
- Viral gastroenteritis research and epidemiology
- Disaster Response and Management
- Infection Control in Healthcare
- Long-Term Effects of COVID-19
- Vector-borne infectious diseases
- Single-cell and spatial transcriptomics
- COVID-19 Impact on Reproduction
- Congenital Diaphragmatic Hernia Studies
- Herpesvirus Infections and Treatments
- Influenza Virus Research Studies
- Dermatological and COVID-19 studies
- Medical Device Sterilization and Disinfection
National Institute of Allergy and Infectious Diseases
2016-2025
National Institutes of Health
2015-2025
University of Concepción
2021
San Sebastián University
2021
State Key Laboratory of Virology
2016
Centers for Disease Control and Prevention
2015
Centers for Disease Control and Prevention
2015
Public Health Agency of Canada
2015
Kenya Medical Research Institute
2015
Ministry of Health and Social Welfare
2015
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the disease 2019 (COVID-19) pandemic3. Vaccines are an essential countermeasure urgently needed to control pandemic4. Here we show that adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes spike protein of SARS-CoV-2, immunogenic mice elicites a robust humoral cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated...
An outbreak of coronavirus disease 2019 (COVID-19), which is caused by a novel (named SARS-CoV-2) and has case fatality rate approximately 2%, started in Wuhan (China) December 20191,2. Following an unprecedented global spread3, the World Health Organization declared COVID-19 pandemic on 11 March 2020. Although data humans are emerging at steady pace, some aspects pathogenesis SARS-CoV-2 can be studied detail only animal models, repeated sampling tissue collection possible. Here we show that...
To the Editor A novel human coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, referred to as HCoV-19 here) that emerged in Wuhan, China late 2019 is causing a pandemic 1 . Here, we analyze aerosol and surface stability of compare it with SARS-CoV-1, most closely related coronavirus. We evaluated SARS-CoV-1 aerosols on different surfaces estimated their decay rates using Bayesian regression model (see Supplementary Appendix). All experimental measurements are...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019 1,2 and is responsible for the COVID-19 pandemic 3 . Vaccines are an essential countermeasure urgently needed to control 4 Here, we show that adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding spike protein of SARS-CoV-2, immunogenic mice, eliciting a robust humoral cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG subclass cytokine expression profiling. A single...
Single-cell RNA sequencing of lungs SARS-CoV-2–infected African green monkeys reveals virus replication and host response dynamics in vivo.
Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and vivo efficacy against coronaviruses. Here, we tested the of remdesivir treatment rhesus macaque model SARS-CoV-2 infection.To evaluate effect on disease outcome, used recently established infection that results transient lower respiratory tract disease. Two groups six macaques were infected treated intravenous or an equal volume vehicle solution once daily. Clinical, virological...
An outbreak of a novel coronavirus, now named SARS-CoV-2, causing respiratory disease and ~2% case fatality rate started in Wuhan, China December 2019. Following unprecedented rapid global spread, the World Health Organization declared COVID-19 pandemic on March 11, 2020. Although data humans are emerging at steady pace, certain aspects pathogenesis SARS-CoV-2 can only be studied detail animal models, where repeated sampling tissue collection is possible. Here, we show that causes infected...
The unprecedented pandemic of SARS-CoV-2 has created worldwide shortages personal protective equipment, in particular respiratory protection such as N95 respirators. transmission is frequently occurring hospital settings, with numerous reported cases nosocomial highlighting the vulnerability healthcare workers. In general, respirators are designed for single use prior to disposal. Here, we have analyzed four readily available and often used decontamination methods: UV, 70% ethanol, 70C heat...
Until the recent emergence of two human-pathogenic tick-borne phleboviruses (TBPVs) (severe fever with thrombocytopenia syndrome virus [SFTSV] and Heartland virus), TBPVs have been neglected as causative agents human disease. In particular, no studies addressed global distribution TBPVs, consequently, our understanding mechanism(s) underlying their evolution remains poor. order to provide a useful tool for ecological epidemiological study we established simple system that can detect all...
We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. previously showed protection disease pneumonia hamsters vaccinated with a single dose nCoV-19. Here, we observe 9.5-fold reduction virus neutralizing antibody titer hamster sera compared to B.1.1.7. Vaccinated challenged or do not lose weight control animals. In contrast animals, the lungs animals show any gross lesions. Minimal no viral subgenomic...
Since the emergence of SARS-CoV-2, five different variants concern (VOCs) have been identified: Alpha, Beta, Gamma, Delta, and Omicron. Because confounding factors in human population, such as preexisting immunity, comparing severity disease caused by VOCs is challenging. Here, we investigate progression rhesus macaque model upon inoculation with Omicron BA.1, BA.2 VOCs. Disease macaques inoculated BA.1 or was lower than those Delta resulted significantly viral loads nasal swabs, bronchial...
We compared virus replication and host responses in human alveolar epithelium infected with highly pathogenic avian influenza (HPAI) A(H5N1) viruses. A/Vietnam/1203/2004 replicated most efficiently, followed by A/Texas/37/2024, then A/bovine/Ohio/B24OSU-342/2024. Induction of interferon-stimulated genes was lower A/Texas/37/2024 A/bovine/Ohio/B24OSU-342/2024, which may indicate a reduced disease severity those
The unprecedented pandemic of SARS-CoV-2 has created worldwide shortages personal protective equipment, in particular respiratory protection such as N95 respirators. transmission is frequently occurring hospital settings, with numerous reported cases nosocomial highlighting the vulnerability healthcare workers. In general, respirators are designed for single use prior to disposal. Several groups have addressed potential re-use from a mechanical or decontamination perspective. Here, we...
A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03099-2
Post-exposure highly potent human monoclonal antibodies target Andes hantavirus glycoprotein in a hamster cardiopulmonary syndrome model.
The ongoing Ebola outbreak in West Africa has resulted 28 646 suspected, probable, and confirmed virus infections. Nevertheless, malaria remains a large public health burden the region affected by outbreak. A joint Centers for Disease Control Prevention/National Institutes of Health diagnostic laboratory was established Monrovia, Liberia, August 2014, to provide diagnostics virus.All blood samples from suspected virus-infected patients admitted Médecins Sans Frontières ELWA3 treatment unit...
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies. Here we assessed the hydroxychloroquine (HCQ), interest COVID-19 management, in two animal models. When used prophylaxis or treatment neither standard malaria dose (6.5 mg/kg) nor high (50 HCQ had any beneficial effect on disease SARS-CoV-2 kinetics (replication/shedding) Syrian...
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the hydroxychloroquine (HCQ), interest management, in 2 animal disease models. The standard malaria HCQ prophylaxis (6.5 mg/kg given weekly) and treatment daily) did not significantly benefit outcome, nor it reduce SARS-CoV-2...
Infections with New World hantaviruses are associated high case fatality rates, and no specific vaccine or treatment options exist. Furthermore, the biology of hantaviral GnGc complex, its antigenicity, fusion machinery poorly understood. Protective monoclonal antibodies against have potential to be developed into therapeutics disease also great tools elucidate glycoprotein complex.